Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $371.00 at TD Cowen

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price boosted by equities research analysts at TD Cowen from $282.00 to $371.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective would suggest a potential upside of 25.13% from the stock’s current price.

A number of other research analysts also recently weighed in on ALNY. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Raymond James raised their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 18th. Finally, Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $290.86.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $296.48 on Monday. The firm has a market cap of $37.50 billion, a price-to-earnings ratio of -110.63 and a beta of 0.39. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a 50-day moving average price of $272.83 and a two-hundred day moving average price of $219.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. The company’s quarterly revenue was up 107.0% on a year-over-year basis. During the same quarter last year, the business posted ($2.21) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock worth $13,595,460 in the last 90 days. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $26,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $30,000. Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $51,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1,237.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 297 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.